GlassScriptPhysician profile
Anna Ziganshina
NPI 1629431630
$6,816.74
in general payments reported to CMS, 2019-2025
37 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $729 · 2023: $1,985 · 2024: $2,596 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,651 · Education: $43.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,651.01 |
| Education | $43.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,263.24 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $992.83 | 2022-2025 | Jardiance, Mounjaro, Lyumjev |
| Xeris Pharmaceuticals, INC. | $736.75 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $605.03 | 2021-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $479.65 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $243.85 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.52 | 2022-2024 | Jardiance |
| Ascendis Pharma Endocrinology INC | $200.73 | 2024-2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $186.63 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $169.96 | 2021-2025 | Strensiq |
| Abbvie INC. | $154.66 | 2023-2024 | Synthroid, Botox |
| Antares Pharma, INC. | $145.05 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Ascensia Diabetes Care US INC. | $114.60 | 2023-2024 | |
| Medtronic, INC. | $105.04 | 2022-2024 | Minimed 780g, Minimed 770g |
| Insulet Corporation | $101.50 | 2023-2024 | Omnipod |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $98.37 | 2023-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $86.93 | 2022-2023 | Unithroid |
| Dexcom, INC. | $83.29 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $80.24 | 2024 | Veozah, Myrbetriq |
| Halozyme INC | $72.54 | 2023 | |
| Cequr Corporation | $72.31 | 2023 | Cequr Simplicity |
| Kyowa Kirin, INC. | $67.52 | 2024-2025 | Crysvita |
| Tandem Diabetes Care, INC. | $61.18 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $60.52 | 2023-2024 | NP Thyroid 60 |
| Amphastar Pharmaceuticals, INC. | $58.58 | 2023-2024 | Baqsimi |
| Horizon Therapeutics Plc | $55.92 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $50.32 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $28.55 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $28.12 | 2023 | |
| Almatica Pharma LLC | $26.10 | 2024 | Teriparatide |
| Lifescan, INC. | $25.98 | 2022 | |
| Ibsa Pharma INC. | $24.92 | 2023 | Tirosint, Licart |
| Mannkind Corporation | $24.39 | 2023 | Afrezza |
| Azurity Pharmaceuticals, INC. | $23.49 | 2023 | Horizant |
| Neurocrine Biosciences, INC. | $21.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.54 | 2023 | Farxiga |
| Amryt Pharma Holdings LTD | $19.51 | 2023 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ziganshina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.